Analysts Set Tempus AI, Inc. (NASDAQ:TEM) Price Target at $58.55

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) has received an average rating of "Moderate Buy" from the twelve research firms that are presently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $58.55.

Several equities analysts have recently commented on the stock. Wolfe Research assumed coverage on shares of Tempus AI in a research report on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $56.00 price target on shares of Tempus AI in a report on Tuesday, January 14th. Bank of America lifted their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a report on Friday, December 13th. TD Cowen reaffirmed a "buy" rating and set a $74.00 price target (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Finally, Stifel Nicolaus lowered shares of Tempus AI from a "buy" rating to a "hold" rating and lifted their price target for the company from $45.00 to $65.00 in a report on Monday, November 11th.

Insiders Place Their Bets

In other news, major shareholder Bradley A. Keywell sold 395,800 shares of the company's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total value of $16,999,610.00. Following the sale, the insider now directly owns 16,164,449 shares of the company's stock, valued at approximately $694,263,084.55. This represents a 2.39 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO James William Rogers sold 31,780 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $82.33, for a total transaction of $2,616,447.40. Following the completion of the sale, the chief financial officer now directly owns 189,320 shares in the company, valued at approximately $15,586,715.60. This represents a 14.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,583,467 shares of company stock valued at $130,542,311 in the last ninety days.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new stake in shares of Tempus AI in the 4th quarter valued at $108,000. Voloridge Investment Management LLC bought a new stake in shares of Tempus AI in the 4th quarter valued at $11,826,000. Two Sigma Advisers LP bought a new stake in shares of Tempus AI in the 4th quarter valued at $625,000. ProShare Advisors LLC bought a new stake in shares of Tempus AI in the 4th quarter valued at $244,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Tempus AI during the 4th quarter valued at $1,034,000. 24.22% of the stock is owned by institutional investors.

Tempus AI Stock Down 11.2 %

Shares of NASDAQ:TEM opened at $68.09 on Wednesday. The firm has a 50 day moving average of $50.29 and a 200-day moving average of $51.65. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI has a 12 month low of $22.89 and a 12 month high of $91.45.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.